Key result
Pulmonary arterial hypertension in the elderly is increasingly diagnosed but often delayed due to comorbidities, and this population continues to have disproportionately lower survival rates.
PAH in the elderly is an increasingly recognized clinical entity that requires careful differentiation from left heart disease, cautious use of targeted therapies due to comorbidities and drug interactions, and multidisciplinary management including pulmonary rehabilitation.
Supports cautious PAH differentiation from HFpEF and therapy selection in elderly; leaves open age-specific trials.
Pulmonary hypertension (PH) is a rare and devastating disease characterized by progressive increases in pulmonary arterial pressure and pulmonary vascular resistance, which eventually leads to right ventric-ular failure and death. Pulmonary arterial hypertension (PAH) (World Health Organization Group I), a subset of PH, and may be idiopathic in nature or associated with other systemic conditions and is thought to most commonly effect women, the majority of whom are of childbearing age. However, PAH in the elderly population is being increasingly diagnosed creating clinical considerations that had once not been considered. Often in an elderly population the diagnosis of PAH may be delayed due to chronic comorbid conditions such as coronary artery disease or other dyspneic conditions. Though survival and clinical outcomes have improved, the elderly population continues to have disproportionately lower survival rates. High clinical suspicion of PAH warrants a complete diagnostic workup with right heart catheterization. Upon diagnosis, PAH specific therapy should be initiated with possible drug interactions in mind. Adjuvant pulmonary rehabilitation should be considered as a conservative measure with definitive results. Finally, psychosomatic aspects of the disease should also be considered in elderly populations.
No takes yet. Share an insight, caveat, or question.
Rothbard et al. (2018) conducted a review in Pulmonary arterial hypertension. Pulmonary arterial hypertension in the elderly is increasingly diagnosed but often delayed due to comorbidities, and this population continues to have disproportionately lower survival rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: